Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Principal Investigator/Program Director (Last, First, Middle): Greene, John N BIOGRAPHICAL SKETCH NAME POSITION TITLE John N Greene Professor, Division of Infectious Disease & International Medicine eRA COMMONS USER NAME EDUCATION/TRAINING INSTITUTION AND LOCATION College of William and Mary, Williamsburg, Virginia University of South Florida College of Medicine, Tampa, Florida University of South Florida College of Medicine, Tampa, Florida University of South Florida College of Medicine, Tampa, Florida DEGREE (if applicable) YEAR(s) FIELD OF STUDY BS 1982 Biology and Psychology MD 1986 Medicine Residency 1986-1989 Internal Medicine Fellowship 1989-1991 Infectious Disease A. Positions and Honors Positions and Employment 1991-present 1991-present 1991-present 1997-present 2000-present 2001-present 2002-2003 Director, Employee Health, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL Chief Epidemiologist, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL Chief, Division of Infectious Disease and International Medicine, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL Director, Epidemiology, University of South Florida College of Medicine, Tampa, FL Joint Appointment, Department of Internal Medicine, University of South Florida College of Medicine, Tampa, FL Professor of Medicine, Department of Internal Medicine, Division of Infectious Disease, University of South Florida College of Medicine, Tampa, FL President, Medical Staff, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL Other Experience and Professional Memberships 1989-present 1992-present 1992-present 1995-present 1996-present 1998-present 1998-present 1998-present 1999-present 2000-present 2000-present 2001-present 1991-present Member, Infectious Disease Society of America Member, Society for Healthcare Epidemiology of America Member-In-Residence, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL Fellow, American College of Physicians Member, American Association for the Advancement of Science Member, Emerging Infections Network of the Infectious Diseases Society of America Member, Alpha Omega Alpha Gamma Chapter at The University of South Florida College of Medicine, Tampa, FL Member, American Society of Microbiology Member, National Comprehensive Cancer Network Member, Interdisciplinary Oncology Program (IOP), H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL Member, Blood and Marrow Transplant Program Multidisciplinary Team, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL Chairman, Ethics Committee, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL Chairman, Infection Control and Epidemiology (ICE) Committee, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL Awards and Honors 1994-present “Moffitt Angel” Award (Patients’ Family Request). PHS 398/2590 (Rev. 09/04) Principal Investigator/Program Director (Last, First, Middle): 1996-present 1997 1998 2003 2003 2005 2006 Greene, John N Citation, “The Best Doctors in America: Southeast Region.” Physician of the Year, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL “Doctor of the Day”, Florida Senate, Tallahassee, FL Nomination for “Outstanding Sophomore Instructor” by the graduating class, University of South Florida College of Medicine, Tampa, FL “The Leonard Tow 2003 Humanism in Medicine” Award, “In Recognition of Exemplary Compassion, Competence and Respect in the Delivery of Care,” The Arnold P. Gold Foundation. Election to the Gold Humanism Honor Society in Recognition of Exemplary Service to Others USF Department of Internal Medicine Faculty Award for H. Lee Moffitt Resident Teaching Award. B. Selected Peer-Reviewed Publications (selected 45 out of 134) 1. Tran HD, Greene JN, Sandin R, Vincent A Strongyloides stercoralis Causing Polymicrobial Empyema in a Cancer Patient. Infections in Medicine, 18(1), January 2001 2. Vincent, AL, Vicencio, RP, Greene, JN, Sandin, RL, Sinnott, JT. Botfly in a Returning Traveler. Infections in Medicine, 18(3), March 2001 3. Tallamraju A, Greene JN, Ganguly R. Infections in Oncology: Facial Cellulitis by Pseudomonas Aeruginosa in a Neutropenic Patient. Cancer Control, 8:364-367, 2001. 4. Tsambiras PE, Patel S, Greene JN, Sandin RL, Vincent AL. Infectious complications of cutaneous t-cell lymphoma. Cancer Control. 8(2):185-8, 2001 Mar-Apr 5. Gill J, Vincent AL, Greene JN, Sandin RL, Sniffen JC. Amebic Liver Abscess. Infections in Medicine, 548-552, December 2001. 6. Greene JN. New Triazoles Hold Promise for Antifungal Prophylaxis against Mould Infections in Transplant Recipients. Abstracts in Hematology and Oncology (editorial comment), 5(3), Page 10, 2002. 7. Thomas G, Greene JN, Sandin RL, Vincent AL, Karl R. Palpitations in a Former Butcher. Infections in Medicine, pp. 212-217, May 2002. 8. Somboonwit C, Greene JN. Diagnostic Methodologies for Invasive Fungal Infections in Hematopoietic Stem-Cell Transplant Recipients. Seminars in Respiratory Infections, 17(2), (June), 2002: pp151-157. 9. Casariego I, Greene JN, Vincent AL, Sandin R. Neutropenic Enterocolitis in Leukemia. Infections in Medicine, 410, September 2002. 10. Rosenbach KA, Nadiminti U, Vincent AL, Erdman DD, Sandin RL, Crowder L, *Greene JN. An Outbreak of keratoconjunctivits in Tampa by Adenovirus type 8. Infections in Medicine, 436-438, September 2002. 11. Ruge DG, Sandin RL, Siegelski SA, Greene JN, Johnson N. Reduction in Blood Culture Contamination Rates by Establishment of Policy for Central Intravenous Catheters. Laboratory Medicine, 33(10), October, 2002: pp 797-800. 12. Greene JN. New Prophylactic and Treatment Strategies Needed to Combat rise in Opportunistic Mould Infections in Setting of HSCT. Abstracts in Hematology and Oncology (editorial comment), 5(3), Page 9, 2002. 13. Greene, JN. Broad-Spectrum Antimicrobials with Activity against Anaerobes Better Choice in Severe or Prolonged Neutropenia. Abstracts in Hematology & Oncology, (editorial comment) 5(1): 2002. 14. Casariego I, Greene JN, Vincent AL, Sandin R. Typhlitis: Images from Previously Reported Cases at H. Lee Moffitt Cancer Center and Research Institute. Infections in Medicine September 2002 Page 410. 15. Kukalja F, Greene JN, Greene KE, Sandin R, Vincent AL. Scombroid Fish Intoxication. Infections in Medicine, December 2002, 19(12), page 574. 16. Jaramillo IM, Greene JN, Sandin RL, Vincent AL. Tuberculosis Presenting as a “Sarcoma”. Infections in Medicine, April 2003, 20(4), page 176. 17. Gill JK, Field T, Vincent AL, Greene JN, Sandin RL, Sinnott JT. Antibiotic Susceptibility among PenicillinResistant Pneumococcal Isolates in Cancer Patients. Infections in Medicine September 2003, 20(9), pp 439-444. PHS 398/2590 (Rev. 09/04) Principal Investigator/Program Director (Last, First, Middle): Greene, John N 18. Vincent AL, Cabrero JE, Greene JN, Sandin RL. Successful Voriconazole Therapy of Disseminated Fusarium Solani in the Brain of a Neutropenic Cancer Patient. Cancer Control 10(5) September/October 2003 19. Baez-Escudero JL, Greene JN, Sandin RL, Vincent AL. Pneumocystis carinii Pneumonia in Cancer Patients. Abstracts in Hematology & Oncology 7(1);24-30:2004. 20. Strickland-Marmol LB, Vincent AL, Laartz BW, Sandin R, Greene JN. Candidemia in Cancer and Bone Marrow Transplant Patients: A 10-Year Retrospective Analysis. Infections in Medicine 21(1) January 2004. 21. Carter WW, Gompf SG, Toney JF, Greene JN, Cutolo EP. Disseminated Acanthamoeba Sinusitis in a Patient With AIDS: A Possible Role for Early Antiretroviral Therapy. The AIDS Reader 14(1) January 2004. 22. Cooper CD, Oehler R, Greene JN, Sandin RL. A Gardener Susceptible to Lymphangitis. Infections in Medicine, February 2004. 23. Brem S, Greene JN, Sandin RL, Letson GD, Vincent AL. Primary Cutaneous Aspergillosis. Images in Infectious Disease, Infections in Medicine March 2004, 21(3), pg. 102. 24. Allison RD, Vincent AL, Greene JN, Sandin RL, Field T. Infectious Pulmonary Nodules Mimicking Lung Carcinoma. Infections in Medicine April 2004, 21(4), pp 181-186. 25. Ramsakal A, Nadaminti H, Field T, Vincent AL, Greene JN, Lall Dass V, Sandin RL. Listeria Infections in Cancer Patient. Infections in Medicine, July 2004, 21(7), pp 345-349. 26. Collins GL, Greene JN, Sandin RL. Special Considerations for the Clinical Microbiology and Virology Laboratories in the Diagnosis of Infections in Cancer Patients. Check Sample, Microbiology No. MB 04-6 (MB-323) Vol. 47(6) August 2004. 27. *Greene JN, Vincent AL, Underhill J. PCR-Confirmed Ovale Malaria in a Traveler. Images in Infectious Disease, Infections in Medicine, 21(10), pg. 495, October 2004 28. Saeed S, Keehn CA, *Greene JN, Sandin RL. Disseminated Mycobacterium Bovis After Intravesicular Bacillus Calmette-Guerin Treatments for Bladder Cancer. Microbiology. Check Sample, No. MB 04-8 (MB-325) Vol. 47 (8), pg. 117 29. Coleman EN, *Greene JN. Pyoderma Gangrenosum. Infections in Medicine, 21(12), pg. 590, December 2004 30. Vincent AL, *Greene JN, Sinnott JT, Rojas CA. Group A Streptococcal Cellulitis with Lymphedema. Infections in Medicine, pg. 317, July 2005 31. Vincent AL, Price R, Field T, *Greene JN, Sandin RL. Addition of Fluoroquinolone Prophylaxis to a Blood and Marrow Transplant Unit to Reduce Gram-Negative Infections. Cancer Control, 12:203-206, 2005 32. *Greene JN, Impact of Fluoroquinolone Prophylaxis on Reduced Infection-Related Mortality Among Patients With Neutropenia and Hematologic Malignancies. Abstracts in Hematology & Oncology (editorial comment), 9(1), Page 13, 2006 33. Klapman JB, *Greene JN, Malafa MP. Mucormycosis Mimicking Obstructing Colon Cancer in a Patient with Acute Promyelocytic Leukemia, Infections in Medicine, 23(5),211-213, 2006 34. Brem, S. *Greene JN, Sandlin RL Letson, D. Vincent AL, Images in Infectious Disease – Primary Cutaneous Aspergillosis, Republished in Infections in Medicine, 23(8S), August 2006 35. Vincent, AL, Melnychuk, I, *Greene JN, Sandlin RL. Images in Infectious Disease Disseminated Toxoplasmosis in a Bone Marrow Transplant Patient, Infections in Medicine 23(8), 390-390a, August 2006 36. *Greene JN, Assessing the Risk of Infections in Patients Receiving Monoclonal Antibody Therapy, Abstract in Hematology and Oncology, pages 7-8, Article ID No. AHO201390, Summer 2006 37. Vincent, AL, *Greene JN, Sandin, R., Recognizing Bronchiolitis Obliterans with Organizing Pneumonia in Cancer Patients, Abstract in Hematology and Oncology, pages 27-30, Article ID No. AHO200810, Summer 2006 38. Vincent, AL, Kurant, DE, *Greene, JN, Sandin, R, Saba, S, Ectopic Paragonimiasis of the Omentum – Infections in Medicine, Images in Infectious Disease, page 316, Vol. 23, No. 7, July 2006 39. Brem, S, *Greene, JN, Sandin, RL, Letson, GD, Vincent, AL, Primary Cutaneous Aspergillosis, Infections in Medicine, Images in Infectious Disease, page18, Vol. 23, No. 8S, Article ID No. iim201349, August 2006 40. Vincent, AL, Melnychuk, I, *Greene, JN, Sandin, RL, Disseminated Toxoplasmosis in a Bone Marrow Transplant Patient, Infections in Medicine, Images in Infectious Disease, pages 390-390a, Vol. 23, No. 8, PHS 398/2590 (Rev. 09/04) Principal Investigator/Program Director (Last, First, Middle): Greene, John N August 2006 41. Greene, MR, Anasetti, C, Sandin, RL, Rolfe, NE, *Greene, JN, CASE REPORT – Development of daptomycin resistance in a bone marrow transplant patient with vancomycin-resistant Enterococcus durans, J Oncol Pharm Practice (2006) 12:179-189 42. Ayala E, Greene, JN, Sandin, RL, Perkins, J, Field, T, Tate, C, Fields, K, Goldstein, S. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in Hematopoietic Stem Cell Transplantation. Bone Marrow Transplant. 2006:37(9):851-856 43. Greene, M, Anasetti, C, Sandin, RL, Rolfe, NE, Greene, JN, Development of daptomycin resistance in a bone marrow transplant patient with vancomycin-resistance in a bone marrow transplant patient with vancomycin-resistant Enterococcus durans. J Oncol Pharm Pract. 2006 Sept; 12(3):179-181 44. Anaissie EJ, Segal BH, Graybill JR, Greene JN. Clinical Research in the Lay Press: Irresponsible Journalism Raises a Huge Dose of Doubt. Clinical Infectious Diseases. October 15, 2006; 43:1031-1039. 45. Kharfan-Dabaja MA, Ayala E, Greene JN, Rojiani A, Anasetti C. Two Cases of Progressive Multifocal Leukoencephalopathy after Allogeneic Hematopoietic Cell Transplantation and a Review of the Literature. Bone Marrow Transplant. 2007;39(2):101-107. C. Ongoing Research Support Pfizer Role: PI 2007-present Retrospective review of Voriconazole vs. Fluconazole for prophylaxes of mold infections with acute GVHD in allogenic HSCT. Role: PI 2002-2007 A Randomized Controlled Trial of Posaconazole (SCH56592) vs. Standard Azole Therapy for the prevention of Invasive Fungal Infections among High Risks Neutropenic Patients. Role: PI 2000-present An Open Randomizes Comparative Multicenter Study of the Efficacy, Safety, and Toleration of Voriconazole vs. Amphotericin B Followed by Other Licensed Antifungal Therapy in the Treatment of Acute Invasive Aspergillosis in Immunocompromised Patients. Merck Role: PI 2005 - 2006 045-00 A Multicenter, open, Non-Comparative Study to Estimate the Safety, Tolerability, and Efficacy of Caspofungin acetate in the treatment of adults with invasive Candida Infections. Schering Plough Role: PI 2005 - 2006 A randomized controlled trial of posaconazole (SCH 56592) vs. standard azole therapy for the prevention of invasive fungal infections among high-risk neutropenic patients. Role: PI 2000-present A Multicenter, Double-Blind, Randomized, Comparative Study to evaluate the Safety, Tolerability, and Efficacy of MK-0991 Versus (Amphotericin B) Liposome for Injection as Empirical Therapy in patients with Persistent Fever and Neutropenia. Merck Role: PI 2000 - 2003 045-00 A multicenter, open, non-comparative study to estimate the safety, tolerability, and efficacy of caspofungin acetate in the treatment of adults with invasive Candida infections.. Role: PI 1999-2003 An Open Label, Non-Comparative Protocol for the Emergency Use of Voriconazole (UK 109,496) in Patients with Life-threatening, Invasive Mycosis who are Failing on Currently Available Antifungal Agents. Pfizer Role: PI 1998 - 2000 A Randomizes, Open Label, Comparative, Multicenter Trial of Voriconazole vs. AmBisome for Empirical Antifungal Therapy in Immunocompromised Patients with Persistent Fever and Neutropenia. PHS 398/2590 (Rev. 09/04) Principal Investigator/Program Director (Last, First, Middle): Greene, John N Pfizer Role: PI 1998 - 2000 An Open Randomized Comparative Multicenter Study of the Efficacy, Safety and Toleration of Voriconazole Vs. Amphotericin B Followed by Other Licensed Antifungal Therapy in the Treatment of Acute Invasive Aspergillosis in Immunocompromised Patients. Merck Role: PI 1998 -2000 A Multicenter, Open, Non Comparative Study to Estimate the Safety, Tolerability, and Efficacy of MK-0991 in the treatment of Invasive Aspergillus Infections in Adults Who are Refractory to or Intolerant of Amphotericin B, Lipid Formulations of Amphotericin B, or Azoles. Fujisawa (Astellas) Role: PI 1998 - 2000 Use of Ambisome for Treatment of Invasive Fungal Infections in Patients Unresponsive or Intolerant to Conventional Amphotericin B. Role: Co-PI ABLC™ vs. Amphotericin B in the Empiric Treatment for Fungal Infection, Liposome. 1994-1997 Role: Co-PI ABCL™ in the Treatment of Definite or Probable Invasive Asperigillosis, Liposome. 1994-1997 SmithKline Beecham Role: Co-PI 1994-1997 Multicenter Study to Assess Penciclovir for the Treatment of Mucocutaneous Herpes Simplex Infection in Immunocompromised Patients. Bayer Role: Co-PI 1993-1997 Fever Study V: Randomized Placebo-Controlled Intravenous Ceftazidime vs. Oral Ciprofloxacin and Augmentin in Febrile Neutropenic Cancer Patients. Role: Co-PI 1992-1997 Open Label, Randomized Comparison of Two Dose Levels of Amphocil in Patients Who have Failed Prior Therapy with Amphotericin B, Liposome. PHS 398/2590 (Rev. 09/04)